Naltrexone at standard doses (50 mg) is an FDA-approved drug used to treat opioid and alcohol dependency. It works by blocking opioid receptors in the brain. At a much lower dose — 1.5 to 4.5 mg — it appears to work through an entirely different mechanism: a brief, temporary receptor blockade that causes the body to compensate by upregulating endorphin production. This rebound effect has broad immunomodulatory consequences that are remarkably relevant to the pattern of dysfunction seen in chronic Lyme disease.
LDN is a prescription medication. It must be obtained through a doctor. In most countries it needs to be compounded by a specialised pharmacy, as the standard 50 mg tablets are not suitable for the low doses required.
What Lyme does to the immune system
To understand why LDN is relevant, it helps to understand what Lyme disease actually does to immune function — because this is what persists long after the bacteria itself is controlled.
Borrelia activates Toll-like receptors (TLRs) on immune cells, triggering an inflammatory cytokine cascade: IL-6, TNF-α, and TGF-β are chronically elevated in Lyme patients. Even after antibiotic treatment reduces bacterial load, this cytokine pattern can continue — driven by residual antigens, immune memory, or damage to self-regulatory mechanisms. These elevated cytokines are responsible for a significant proportion of Lyme symptoms: fatigue, brain fog, pain, and mood disturbance.
The brain's immune cells — microglia — use TLRs to detect and respond to pathogens. In chronic Lyme, these cells become persistently hyperactivated, producing a continuous stream of inflammatory signals in the central nervous system. This neuroinflammation is associated with the cognitive symptoms that patients describe as brain fog, and with the neuropathic pain and mood disturbances that conventional neurology often struggles to explain. Microglial overactivation does not switch off automatically when the infection is treated.
Endorphins regulate both pain perception and immune function. They are typically low in patients with chronic inflammatory conditions and autoimmune-pattern diseases — a category that includes many chronic Lyme presentations. Low endorphin levels correlate with immune dysregulation, heightened pain sensitivity, and persistent fatigue. No conventional antibiotic treatment addresses this depletion.
The mechanism — step by step
LDN is taken at bedtime. For 3–4 hours, it occupies opioid receptors — blocking endorphins from binding. This is too brief to produce the effects seen at full naltrexone doses.
The body detects the blockade and responds by producing more endorphins and increasing the sensitivity of opioid receptors. By morning, the naltrexone has cleared — but endorphin levels are elevated and remain so throughout the day.
Separately from the endorphin mechanism, LDN at low doses blocks Toll-like receptor 4 (TLR4) on microglial cells and peripheral immune cells. TLR4 is the same receptor that Borrelia activates to trigger cytokine cascades. By blocking it, LDN interrupts the ongoing inflammatory signal — even when no active infection remains to trigger it.
The combined effect: IL-6, TNF-α, and TGF-β — the inflammatory markers chronically elevated in Lyme — are reduced. T-regulatory cells function better, shifting the immune response away from the chronic Th1 inflammatory pattern toward a more balanced state. Natural killer cells improve in number and function.
Reduced neuroinflammation, less pain, improved energy, better cognition, stabilised mood. The effect builds gradually — most patients notice meaningful change at 8–12 weeks at therapeutic dose. Some notice changes earlier; some take longer.
What the data shows
Dr. Horowitz — one of the most experienced Lyme clinicians in the United States and author of Why Can't I Get Better? — administered LDN at 4.5 mg to 500 patients with Lyme disease and Multiple Chronic Infectious Disease Syndrome (MCIDS). Approximately 75% reported significant reduction in fatigue, myalgia, and arthralgia. This is the largest reported clinical dataset for LDN in Lyme disease. It is an open-label study without a control group, but the scale and consistency of results are notable.
Because fibromyalgia symptoms overlap substantially with chronic Lyme (fatigue, widespread pain, cognitive impairment), evidence from fibromyalgia trials is relevant. A Stanford pilot study found significant pain reduction after 12 weeks of LDN. A randomised trial in Crohn's disease showed reduced disease activity. Multiple sclerosis studies show improved quality of life in many patients. The shared mechanism — TLR4 blockade, microglial calming, cytokine normalisation — is consistent across these conditions and with the Lyme pattern.
Naltrexone is a decades-old generic drug costing pennies to manufacture. No pharmaceutical company has a financial incentive to fund a large clinical trial for a new indication they cannot patent. The LDN Research Trust and individual clinicians have driven the evidence forward on minimal budgets. The absence of an RCT reflects the economics of drug research, not a signal that the approach does not work.
Four situations where LDN is particularly worth considering
When Lyme triggers autoimmune-like conditions — Hashimoto's, rheumatoid-pattern joint disease, lupus-like presentation — LDN's immune-balancing mechanism is directly relevant. This is when some clinicians introduce it from the beginning of treatment.
Antibiotics have been tried. Herbal protocols have been tried. The infection appears controlled. But fatigue, brain fog, and pain persist. This pattern — immune dysregulation without active infection — is precisely what LDN is designed for.
Progress has stalled. Improvement has plateaued but not reached a satisfactory level. LDN as an adjunct to ongoing treatment has helped some patients break through this pattern — particularly when neurological symptoms are dominant.
MCAS is increasingly recognised as a complication of tick-borne illness. LDN's ability to reduce mast cell hyperreactivity makes it specifically useful in this subset of patients, where multiple other treatments are poorly tolerated due to sensitivity reactions.
Dosing — how it is typically used
Safety profile — genuinely good, with a few caveats
LDN has a notably clean safety profile compared to most prescription treatments used in chronic illness. The side effects that do occur are typically mild, dose-dependent, and manageable.
- Vivid dreams — the most frequently reported side effect. Usually resolves within 1–2 weeks as the body adjusts. Switching to morning dosing resolves it if it persists.
- Mild insomnia — occasional, usually in the first 1–2 weeks of a new dose.
- Mild anxiety or agitation — in a small minority; reduces with dose titration.
- Temporary symptom flare — some patients experience brief worsening when starting, as the immune system adjusts. Typically resolves within 2 weeks.
LDN blocks opioid receptors. If you are taking any opioid medication — including tramadol, codeine, morphine, or oxycodone — LDN will precipitate acute opioid withdrawal. This is a hard contraindication. Do not use LDN if you are on opioid pain management. This must be discussed with your prescribing doctor before starting.
Patients on immunosuppressant medications (for transplants, autoimmune disease) should discuss LDN with their specialist — the immunomodulatory effect could theoretically interact with immunosuppression protocols. Similarly, thyroid medication doses may need adjustment as LDN can affect thyroid function in some patients.
Other approaches in this section
Physical supportive therapies — Bowen technique, infrared sauna, and acupuncture — address the body's physical and autonomic state rather than targeting the infection directly. For patients dealing with pain, fatigue, and nervous system dysregulation, they can meaningfully complement approaches like LDN.
Healing mentality checkpoint
LDN is not dramatic. It does not produce the intensity of response that HBOT or ozone might in the early stages. It works slowly, at the level of regulation rather than attack. For patients conditioned to expect strong treatments producing strong reactions, this can feel like nothing is happening. The 8–12 week window before meaningful assessment is real — patience here is not passive, it is part of the protocol.
Read about healing mentality →Sources & further reading
- Horowitz R. — open-label study of LDN in 500 Lyme/MCIDS patients; Why Can't I Get Better?, St. Martin's Press (2013)
- Younger J., Mackey S. — fibromyalgia pilot study, Stanford University (2009)
- Parkitny L., Younger J. — reduced pro-inflammatory cytokines after eight weeks of LDN for fibromyalgia, Biomedicines (2017)
- Maderis T. — LDN for Lyme disease: clinical overview (drtoddmaderis.com)
- Ross M. — Low-dose naltrexone in Lyme disease (treatlyme.com)
- LDN Research Trust — ldnresearchtrust.org
- Cameron D. — Could low-dose naltrexone help Lyme disease patients? (danielcameronmd.com)
Last updated: March 2026